Darzalex combo up for EU approval for multiple myeloma patients
Johnson & Johnson (J&J) is asking regulatory authorities…
Myeloma
Myeloma overview
Myeloma is a rare blood cancer that begins in plasma cells, a type of white blood cell normally responsible for producing antibodies that help fight off infectious pathogens and other threats.
Read moreMyeloma treatment
While myeloma treatment can drive the disease into remission, sometimes for long periods of time, the cancer will often come back after a few months or years, and additional treatments will be needed.
Read moreLatest news
Carvykti found effective at treating multiple myeloma in real world
Real-world treatment with the cell therapy Carvykti (ciltacabtagene autoleucel)…
New US approval sought for Darzalex Faspro quadruple therapy
Johnson & Johnson (J&J) is seeking U.S. Food…
Carvykti lowering risk of death as second-line myeloma therapy: Trial
A single infusion of the cell therapy Carvykti (ciltacabtagene…
FDA approves Sarclisa regimen as first-line treatment for myeloma
The U.S. Food and Drug Administration has approved Sanofi’s…
FDA grants Poseida’s CAR T-cell therapy RMAT status for RRMM
The U.S. Food and Drug Administration (FDA) has granted…
